Imatinib-d3

Product description： Imatinib-d3 is intended for use as an internal standard for the quantification of imatinib by GC- or LC-MS. Imatinib is an inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit.1 It inhibits ligand-stimulated autophosphorylation of PDGFR and c-Kit (IC50s = ~0.3 and ~0.1 μM, respectively).Imatinib inhibits the proliferation of Bcr-Abl-dependent R10(–) cells (IC50s = ~35-40 nM) and HMC-1cells expressing constitutively active c-Kit in a concentration-dependent manner.1,3 It prolongs survival in a mouse model of chronic myeloid leukemia when administered at a dose of 100 mg/kg twice per day.4 Imatinib (25 and 50 µM) also inhibits the replication of Middle East respiratory syndrome coronavirus(MERS-CoV) and severe acute respiratory syndrome CoV (SARS-CoV) in Vero E6 cells.5 It reduces viral titers in Vero cells infected with infectious bronchitis virus (IBV), a coronavirus, when used at a concentration of 10 µM via inhibition of IBV surface glycoprotein protein-induced syncytia formation and virus-cell fusion.6 Formulations containing imatinib have been used in the treatment of various cancers. Application： Genfatinib-d3 (Imatinib-d3) is the labeled analogue of Genfatinib, a treatment of chronic myeloid leukemia (CML). It is a COVID19-related research product.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet